NetApp Announces Integrated Solution with AWS Outposts for Hybrid Cloud Deployments

1.12.2024 20:00:00 CET | Business Wire | Press release

New integration simplifies the use of NetApp block storage with AWS Outposts

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced NetApp on-premises enterprise storage arrays for AWS Outposts, a new integrated solution allowing AWS Outposts customers to simplify the use of external block data volumes running on NetApp on-premises enterprise storage arrays in AWS Outposts deployments directly through the Amazon Web Services (AWS) Management Console. AWS Outposts is a family of fully managed solutions delivering AWS infrastructure and services to virtually any on-premises or edge location for a truly consistent hybrid experience. This solution simplifies hybrid cloud deployments by combining NetApp’s unified data storage and intelligent services with powerful cloud infrastructure offered by AWS Outposts, helping customers optimize cloud deployments on-premises and at the edge.

“Whether customers are looking to use hybrid cloud infrastructure to increase resiliency or improve compliance, leveraging NetApp storage in AWS Outposts can help customers run applications securely and efficiently at the edge,” said Jonsi Stefansson, Senior Vice President and Chief Technology Officer at NetApp. “This solution makes it simpler for customers to leverage NetApp intelligent data infrastructure to manage their data in AWS Outposts deployments. By automating volume attachments, IT teams can now tap into the efficiency and power of NetApp on-premises storage arrays to power critical workloads.”

Customers with Outpost servers or racks can now use the AWS Management Console to simplify the use of external block data volumes for enterprise applications and database workloads running on Outposts and NetApp on-premises enterprise storage arrays. Customer benefits include:

Simplified User Experience: With this solution, customers can attach block data volumes backed by NetApp on-premises enterprise storage arrays to Amazon Elastic Compute Cloud (Amazon EC2) instances on Outposts directly from the AWS Management Console. This simplifies the user experience by automating volume attachments.
Resilient and Optimized Infrastructure: The solution allows customers to use the capabilities of NetApp’s intelligent data infrastructure such as NetApp SnapMirror® and NetApp Snapshot™ while tapping into the storage efficiencies in Outpost deployments for a resilient, compliant, and optimized infrastructure.
Seamless Hybrid Cloud: By leveraging NetApp’s unified approach to data storage, AWS Outposts users will have a seamless and certified hybrid cloud experience that uses industry-leading tools and services to manage and protect their data in Outposts deployments, AWS Local Zones deployments using Cloud Volumes ONTAP®, the rest of their own data centers, and the cloud when using services such as Amazon FSx for NetApp ONTAP.

Additionally, Spot by NetApp is releasing new capabilities for its automated infrastructure optimization solution for containers and Kubernetes, Spot Ocean. As organizations scale their cloud Kubernetes operations to meet increasing application workload demands, they need a solution that helps them optimize their infrastructure while controlling costs. The new capabilities in Spot Ocean help organizations achieve those goals with a new fast-response auto-scaler that ensures clusters have the infrastructure to meet workload requirements, a dynamic commitment utilization process that uses available resources before provisioning on-demand or preemptive instances, and a new dashboard that provides more visibility and insights into cost optimization efforts and infrastructure efficiency.

To explore these new capabilities and learn how NetApp can enhance your AWS environment, visit the NetApp booth #1748 at AWS re:Invent in Las Vegas from December 2-6, 2024.

Additional Resources

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241201494379/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom